HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 282, Issue 26, 18895-18906, June 29, 2007

This Article Full Text Full Text (PDF) Supplemental Data All Versions of this Article: 282/26/18895    most recent M700373200v2 M700373200v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tampellini, D. Articles by Gouras, G. K. Search for Related Content PubMed PubMed Citation Articles by Tampellini, D. Articles by Gouras, G. K. Related Collections Papers Of The Week Social Bookmarking                      What's this?

Internalized Antibodies to the A Domain of APP Reduce Neuronal A and Protect against Synaptic Alterations^*

From the Department of Neurology and Neuroscience, Weill Medical College of Cornell University, New York, New York 10021

Immunotherapy against -amyloid peptide (A) is a leading therapeutic direction for Alzheimer disease (AD). Experimental studies in transgenic mouse models of AD have demonstrated that A immunization reduces A plaque pathology and improves cognitive function. However, the biological mechanisms by which A antibodies reduce amyloid accumulation in the brain remain unclear. We provide evidence that treatment of AD mutant neuroblastoma cells or primary neurons with A antibodies decreases levels of intracellular A. Antibody-mediated reduction in cellular A appears to require that the antibody binds to the extracellular A domain of the amyloid precursor protein (APP) and be internalized. In addition, treatment with A antibodies protects against synaptic alterations that occur in APP mutant neurons.

Received for publication, January 12, 2007 , and in revised form, March 30, 2007.

^* This work was supported in part by the Dana Foundation, the Alzheimer's Association, the American Health Assistance Foundation, National Institutes of Health Grants NS045677 and AG028174 (to G. K. G.), and by a doctoral fellowship from Fundação para a Ciência e a Tecnologia, Portugal (to C. G. A.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The on-line version of this article (available at http://www.jbc.org) contains supplemental Figs. S1–S12 and movie S1.

This article was selected as a Paper of the Week.

¹ To whom correspondence should be addressed: Dept. of Neurology & Neuroscience, Weill Medical College of Cornell University, 525 East 68th St. New York, NY 10021. Tel.: 212-746-6598; Fax: 212-746-8741; E-mail: gkgouras{at}med.cornell.edu.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				G. Habicht, C. Haupt, R. P. Friedrich, P. Hortschansky, C. Sachse, J. Meinhardt, K. Wieligmann, G. P. Gellermann, M. Brodhun, J. Gotz, et al. Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing A protofibrils PNAS, December 4, 2007; 104(49): 19232 - 19237. [Abstract] [Full Text] [PDF]

				D. V. Venkitaramani, J. Chin, W. J. Netzer, G. K. Gouras, S. Lesne, R. Malinow, and P. J. Lombroso {beta}-Amyloid Modulation of Synaptic Transmission and Plasticity J. Neurosci., October 31, 2007; 27(44): 11832 - 11837. [Full Text] [PDF]

				A. A. Asuni, A. Boutajangout, D. Quartermain, and E. M. Sigurdsson Immunotherapy Targeting Pathological Tau Conformers in a Tangle Mouse Model Reduces Brain Pathology with Associated Functional Improvements J. Neurosci., August 22, 2007; 27(34): 9115 - 9129. [Abstract] [Full Text] [PDF]